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Background: Perioperative goal directed therapy (GDT) can substantially improve the outcomes of high risk surgical
patients as shown by many clinical studies. However, the approach needs initial investment and can increase the
already very high staff workload. These economic imperatives may be at least partly responsible for weak adherence to
the GDT concept. A few models are available for the evaluation of GDT cost-effectiveness, but studies of real economic
data based on a recent clinical trial are lacking. In order to address this we have performed a retrospective analysis of
the data from the “Intraoperative fluid optimization using stroke volume variation in high risk surgical patients” trial
(ISRCTN95085011).
Methods: The health-care payers perspective was used in order to evaluate the perioperative hemodynamic
optimization costs. Hospital invoices from all patients included in the trial were extracted. A direct comparison between
the study (GDT, N = 60) and control (N = 60) groups was performed. A cost tree was constructed and major cost drivers
evaluated.
Results: The trial showed a significant improvement in clinical outcomes for GDT treated patients. The mean cost per
patient were lower in the GDT group 2877 ± 2336€ vs. 3371 ± 3238€ in controls, but without reaching a statistical
significance (p = 0.596). The mean cost of all items except for intraoperative monitoring and infusions were lower for
GDT than control but due to the high variability they all failed to reach statistical significance. Those costs associated
with clinical care (68 ± 177€ vs. 212 ± 593€; p = 0.023) and ward stay costs (213 ± 108€ vs. 349 ± 467€; p = 0.082) were the
most important differences in favour of the GDT group.
Conclusions: Intraoperative fluid optimization with the use of stroke volume variation and Vigileo/FloTrac system
showed not only a substantial improvement of morbidity, but was associated with an economic benefit. The
cost-savings observed in the overall costs of postoperative care trend to offset the investment needed to run
the GDT strategy and intraoperative monitoring.
Trial registration: ISRCTN95085011
Keywords: Hemodynamic optimization, Cost-effectiveness, Fluid optimizationBackground
Due to the recent economic situation in Europe financial
resources in healthcare are becoming increasingly limited.
Under these circumstances cost-effectiveness, or preferably
cost savings, from new therapeutic approaches may be vital
for their adoption, especially, if these new treatments* Correspondence: benesj@fnplzen.cz
Department of Anaesthesia and Intensive Care Medicine, Charles University
Medical School and Teaching Hospital, Alej svobody 80, 304 60 Plzen, Czech
Republic
© 2014 Benes et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orare accompanied by higher initial acquisition or mainten-
ance costs. Hemodynamic optimization and goal directed
therapy (GDT) of high risk surgical patients improves
postoperative outcomes by decreasing the number of
complications and hospital length of stay as showed by
many clinical trials and meta-analyses [1-3]. Additionally,
according to pooled data from recently published meta-
analysis an impact on postoperative mortality may be
observed in the groups with high control-group mor-
tality [4]. The reality though is that overall adoption oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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American anaesthesiologists [5] and a lack of data on an
economic benefit may be an important reason why. For
example, if a comprehensive investment (financial and
practice orientated) is needed, hospital administrators and
insurance companies may not be willing to cover these
expenses.
There are limited economic data regarding periopera-
tive GDT published so far. In 1997 an economic evalu-
ation of a study by Boyd [6] was performed by Guest
[7] showing a decreased economic burden using pul-
monary artery catheter for preoperative hemodynamic
optimization. Later, similar results were published by
Fenwick [8] based on the Wilson optimization trial [9].
Both of the original clinical studies used pulmonary ar-
tery catheter for guiding fluid optimization and in one
[9] the patients were admitted to the hospital ICU the
day before surgery in order to perform preoperative
tuning-up. Nowadays, neither the device nor the pre-
operative GDT are relevant to contemporary practice.
The development of less invasive devices has enabled
the use of routine GDT in an intermediate to high risk
population and studies performed intraoperatively and
also in the early postoperative period have shown com-
parable results to preoperative treatment. All of these
issues are highly relevant for potential economic deci-
sion making.
More relevant are two recent studies both using an
economic modelling approach based on meta-analysis of
clinical trials. Mowatt et al. [10] performed an economic
evaluation of oesophageal Doppler use where for both
the worst and best scenarios the use of this technology
was deemed cost-effective. Another cost-effectiveness
evaluation was performed by a Swedish group [11]
where data from a mix of different devices and GDT
strategies were used as model inputs applied to the clin-
ical results of elderly patients with hip-fracture. These
results also stressed the potential of perioperative GDT
to be not only cost-effective but also cost saving with
substantial clinical benefits. Nevertheless, despite these
publications an evaluation based on real economic data
coming from a study using less invasive device in high
risk patients is lacking. To address this we decided to
perform a retrospective, health care payers perspective,
economic evaluation of the Intraoperative fluid opti-
misation using stroke volume variation in high risk sur-
gical patients (SVVOPT) trial [12]. Our hypothesis was
that the observed improvement in clinical outcomes
with GDT would result in lower costs compared with
the control arm.
The SVVOPT study used a novel, less invasive Vigileo/
FloTrac system for the intraoperative fluid and hemo-
dynamic optimization of high risk surgical patients. In
total 120 patients were equally and randomly distributedinto intervention (GDT, N = 60) and control group
(Control, N = 60). The goal of fluid intervention in the
GDT group was stroke volume variation (SVV) lower than
10% and cardiac index (CI) higher than 2.5 l/min/m2. In-
fusions of colloids and dobutamine were used in order to
reach these goals. Considerable outcome benefit regarding
number (34 vs. 78; p = 0.007) and rate (18 vs. 35 patients;
p = 0.003) of postoperative complications was observed in
the GDT group using an intention-to-treat approach.
Additionally, in the per protocol analysis of patients with
performed optimization the hospital length of stay was
significantly shorter. There was no difference in number
of deaths, but the study was not designed to be powered
to prove a mortality benefit.
Methods
The original SVVOPT study ran from July 2007 until
May 2009 and enrolled 120 patients equally and ran-
domly distributed into intervention and control groups.
Written informed consent and approval of the local eth-
ics committee of the Charles University Hospital in
Plzen, Czech Republic was provided for the study. All
economic data were routinely collected in the form of
individual invoices issued for the healthcare payer at dis-
charge. In order to avoid bias where possible due to the
retrospective design, two of the authors here (JZ and
AS) who were not part of the original trial and unaware
of the patient treatment group allocation performed the
extraction of the economic data. In order to evaluate the
major drivers the costs were separated into 10 categor-
ies: anaesthesia, monitoring, infusion and blood product
associated costs, further postoperative ward and ICU
stay, clinical examination and procedures, laboratory
diagnostics, antimicrobial agents, radio-diagnostics and
others. In order to try and avoid large confounding fac-
tors, the costs of the surgical procedure, postoperative
analgesia and preoperative stay were excluded from the
final sum. However, in order to fully account the cost of
GDT the monitoring relevant costs (Vigileo device and
60 FloTrac monitoring sets) were captured. These pay-
ments were not reimbursed by the payer, but are rele-
vant for the future decision. As the study was performed
in the Czech Republic some specifics of healthcare reim-
bursement should be mentioned:
 All clinical investigations are evaluated with a
number of points, these points are fully reimbursed
by the insurance company according to the actual
course (this changed once during the study period
and was increased accordingly).
 Some materials used (central venous catheters,
parenteral nutrition, all antimicrobial agents, blood
products, radio-contrast dye and other) are also
reimbursed.
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urinary catheters, usual medication, etc.) are
reimbursed in lump sum payments and are billed in
a per diem fee according to patient category of care.
 Finally, some medical services are neither charged to
the patient nor the payer. From these only the costs
of study specific material were included in the study:
Vigileo machine – 6100 €, FloTrac monitoring sets -
175 € each, and intravenous infusions.
All sums were obtained in Czech Crowns (CZK) and
converted to Euros (€) according to a mean exchange
rate for the study period (25 CZK per 1 €). Any fluctua-
tions in this rate according to data obtained from the
Czech National Bank were very small making the poten-
tial bias irrelevant. No consideration of inflation was in-
cluded in the calculations due to the relatively short
study period.
To assess the economic benefit of the intervention the
following analyses were performed: Firstly, the total
costs of both study groups and subcategories of patients
with and without complications were analyzed. A cost
tree (Figure 1) was constructed for these variables: treat-
ment allocation as first branch and complication occur-
rence (as the major clinical outcome) as the second
branch. For each branch a number of patients, total
costs and their proportions were calculated. It is difficult
to assess the cost-effectiveness ratio for GDT versus con-
trol in this retrospective study as it was underpowered
to demonstrate a mortality benefit and although there was
an obvious morbidity benefit (i.e. fewer complicationsFigure 1 Cost tree for the two treatment arms of the
SVVOPT study.for GDT) no patient related endpoints such as quality of
life were prospectively collected. Therefore rather than
complicate the analysis unnecessarily the results here are
presented only in the form of costs. A discussion on the
implications of this are included at the end of this report.
In addition to the overall cost analysis an analysis of
specific reimbursement groups was performed in order
to identify the major cost drivers and their importance
to the total costs according to the treatment allocation.
The costs are reported as both mean (standard deviation)
and median (interquartile range) as proposed by Briggs
[13] as means are less prone to reduce the impact of ex-
treme values and hence enable better description of costs
across a patients sample. However, nonparametric statistic
tests (Mann–Whitney test, Kruskal-Wallis test) were used
to assess the difference between study groups accordingly.
All calculations were performed using the MedCalc soft-
ware ver. 12.4.0.0. (MedCalc Software, Acacialaan 22,
B-8400 Ostend, Belgium).
Finally, although this study is performed directly from
patient-specific clinical and billing records, for most
readers the costs of different complications may be of
importance especially for the international comparison.
Therefore, we have identified patients having specific
complications in order to evaluate the induced add-
itional costs. Patients were grouped according to the na-
ture of their complications (i.e. none, solely infectious,
solely non-infectious, a mixture). In addition, patients
having a single complication were evaluated for add-
itional costs.
Results
Major clinical results of the study were already men-
tioned and are given in detail elsewhere [12]. Most rele-
vant for this economic analysis are the following: the
intervention reduced the number of complications (34 vs.
78 complications; p = 0.007) and their rate (18 vs. 35
patients in the GDT and Control group respectively;
p = 0.003). The overall hospital length of stay (calculated as
the sum of all stays per group) was 627 vs. 925 days for the
GDT and Control group respectively. In the per protocol
analysis, the median hospital stay was 9 days (8 to 12) in
the GDT group compared to 10 days (8 to 19) in controls
(p = 0.042).
The mean total costs per patient in the intervention
group were 2877 ± 2336 € (mean ± SD) whereas in the
control group they were 3331 ± 3238 €. The overall cost
was 27,255 € higher in the Control group and mean cost
per patient was 454 € in favour of GDT, with large vari-
ability. As described in the cost tree (Figure 1) the mean
cost of those without complications was slightly higher
in the GDT group. Unsurprisingly, the study monitoring
costs contributed the majority (70%) of this difference.
Also, the overall mean costs of patients with complications
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patients with complications though minor in number
(N = 53; 44%) were responsible for the majority of costs
(235,623 €, 63%). The incidence of complications was the
major driving parameter for increased total and mean costs
in the Control group.
An overview of the major health care cost categories is
presented in Table 1. The average costs of care tended
to be lower for GDT versus Control (2877 ± 2336 € vs.
3331 ± 3238 €; p = 0.596) although not statistically sig-
nificant. In fact all costs except those for intraoperative
monitoring and infusions were lower for GDT than con-
trol but due to the high variability most failed to reach
statistical significance. However, the study was not de-
signed to power this comparison and a post-hoc analysis
estimates a sample size of at least 200 patients in each
arm to reach statistical significance. Thus a tendency
for lower costs of postoperative care was observed
(1891 ± 2170 € vs. 2501 ± 3152 €; p = 0.177) and clinical
care related costs (honoraria, examinations and proce-
dures) were significantly decreased in the GDT group
(68 ± 177 € vs. 212 ± 593 €; p = 0.023). For other param-
eters, i.e. ward stay costs (213 ± 108 € vs. 349 ± 467 €;
p = 0.082) and infection associated costs (99 ± 151 € vs.
236 ± 535 €; p = 0.365) only a trend in favour of the
GDT group was observed. As monitoring related costs
(Vigileo machine and monitoring FloTrac kits) were in-
cluded in the calculation the costs of intraoperative care
were bound to be higher in the GDT group (986 ± 351 €Table 1 Cost comparison in major reimbursement categories
GDT
Mean ± SD Med
Total 2877 ± 2336 2181
Intraoperative* 986 ± 351 880
Anaesthesia 493 ± 157 462
Monitoring* 296 ± 0 296
Infusion 37 ± 17 45 (3
Blood products 160 ± 241 0 (0–
Postoperative 1891 ± 2170 1142
Patients care 505 ± 486 328
Clinical examinations/procedures* 68 ± 177 29 (2
Biochemistry 205 ± 138 172
Microbiology diagnostics and antimicrobials 99 ± 151 36 (1
Radiology examinations 34 ± 66 6 (6–
Other 100 ± 122 38 (2
Hospitalization costs 1386 ± 1736 831
Intensive care unit stay costs 1173 ± 1736 637
Ward stay costs 213 ± 108 202
All p values are calculated using the Mann–Whitney test (* marks where p < 0.05).
Abbreviations: SD – standard deviation, IQR – interquartile range.vs. 830 ± 469 €; p = 0.001) but in general, mean intraopera-
tive costs were higher 156 ± 351 € (p = 0.001) and postop-
erative costs lower 609 ± 3152 € (p = 0.177) in the GDT
group.
Additional costs induced by some specific complica-
tions or groups of complication were also evaluated.
This analysis was limited by a low number of patients
having one specific condition only. However, we were
able to identify patients having just infectious complica-
tions (i.e. pneumonia, surgical site, urinary tract and
catheter related blood stream infections), but only one
non-infectious complication (i.e. acute heart failure). The
occurrence of any complication, irrespective of study group
allocation, increased the costs of postoperative care by
2295 ± 3611 € (p < 0.001) with a significant increase in all
major cost driving categories. Mean costs for patients with
and without complications are given in Table 2. For the
groups with different complications the additional sum is
also displayed to enable a direct comparison to data pub-
lished by other authors [14,15].
Discussion
The current study evaluates in a retrospective fashion the
economic implications of intraoperative fluid optimization
guided by stroke volume variation based on previously
published clinical results [12]. The mean cost per patient
in the intervention arm was 2877 ± 2336 € compared to
3331 ± 3238 € in the control group. Overall, the incidence
of postoperative complications was the most important(in Euro)
Control
ian (IQR) Mean ± SD Median (IQR) p value
(1561–3154) 3331 ± 3238 2331 (1540–3687) 0.596
(744–1165)* 830 ± 469 688 (504–1006)* 0.001
(389–591) 540 ± 184 495 (432–636) 0.094
(296–296)* 20 ± 0 20 (20–20)* 0.0001
2–48) 32 ± 17 32 (19–48) 0.173
255) 237 ± 336 80 (0–389) 0.264
(764–2210) 2501 ± 3152 1626 (810–2367) 0.177
(218–582) 912 ± 1429 439 (222–921) 0.125
2–41)* 212 ± 593 38 (25–86)* 0.023
(117–246) 263 ± 271 174 (116–291) 0.702
7–136) 236 ± 535 62 (16 – 194) 0.365
30) 40 ± 68 6 (6–29) 0.944
4–138) 161 ± 262 48 (26–190) 0.570
(544–1570) 1589 ± 1863 1040 (491–1808) 0.459
(205–1480) 1240 ± 1752 704 (0–1409) 0.977
(140–241) 349 ± 467 219 (161–368) 0.082













No complication N = 67 1182 ± 790 863 ± 656 320 ± 185 29 ± 14 152 ± 79 45 ± 54 15 ± 25 78 ± 98
Any complication N = 53 3477 ± 3611 2278 ± 2387 1199 ± 1482 280 ± 640 337 ± 282 322 ± 561 64 ± 90 196 ± 277
Additional costs in specific groups
Infectious N = 31 1789 ± 3262 1102 ± 2113 687 ± 1238 121 ± 304 123 ± 206 285 ± 660 36 ± 72 121 ± 239
Non-infectious N = 7 548 ± 657 −48 ± 456 597 ± 661 439 ± 641 47 ± 154 61 ± 112 35 ± 63 14 ± 88
Multiple/mixed complications N = 15 4155 ± 4434 2743 ± 2887 1411 ± 2065 433 ± 1028 375 ± 370 360 ± 446 81 ± 126 162 ± 391
Additional costs in specific complications
Pneumonia N = 6 1437 ± 4161 1118 ± 373 320 ± 695 26 ± 76 111 ± 244 125 ± 202 11 ± 20 46 ± 188
Surgical site infection N = 7 2119 ± 1040 1486 ± 932 633 ± 274 84 ± 130 158 ± 98 192 ± 163 51 ± 80 148 ± 183
CRBSI N = 9 643 ± 1314 399 ± 1138 244 ± 276 21 ± 40 42 ± 105 132 ± 125 22 ± 41 27 ± 155
UTI N = 9 175 ± 606 66 ± 400 108 ± 292 6 ± 11 75 ± 234 20 ± 111 2 ± 24 5 ± 84
Acute heart failure N = 4 1152 ± 1182 843 ± 1017 309 ± 205 85 ± 113 139 ± 157 111 ± 88 1 ± 10 −28 ± 48
Comparison between the No and Any complications group have been made using the Mann–Whitney test, all other comparisons between subgroups were assessed by the Kruskal-Wallis test using the Conover
post-hoc analysis.
Bold type shows statistical significance against the patients without complications.
Negative number in additional costs: decrease in costs as compared to patients without complication.


















Benes et al. BMC Anesthesiology 2014, 14:40 Page 6 of 8
http://www.biomedcentral.com/1471-2253/14/40cost driver. In addition, our results here detail the incre-
mental costs due to different infectious and non-infectious
complications which will enable a comparison of health
care costs in post-communist European countries to those
from the West.
Economic data and proof of economical benefit are
lacking for many interventions from our daily practice.
Nevertheless the current economic situation in most de-
veloped countries impacts budgets and so economic
analyses of new and existing therapies are becoming in-
creasingly important. This is perhaps more so in post-
socialistic countries of Middle and Eastern Europe as the
shortage of resources is most striking there. Periopera-
tive goal directed hemodynamic optimization is one of
the most promising concepts for clinical benefit in the
postoperative period as its use has been shown to avoid
complications, reduce patient length of stay and reduce
postoperative morbidity. Alas, the concept is still not
widely embraced and is seldom used outside specific
health care facilities. Perceived increased economic bur-
den, anaesthesiologist workload and a lack of proven
economical benefit might be some of the reasons for not
adopting this approach. It is true that there are only lim-
ited economic data to support perioperative GDT al-
though the economic evaluations by Boyd [6,7] and
Wilson [8,9] have both shown cost-effectiveness, but due
to recent developments in the field they are of limited
impact. Many different devices have since replaced the
pulmonary artery catheter in routine use for GDT in
high risk populations and the lower invasiveness in-
creases the number of patients having a potential clinical
benefit [16]. However, the acquisition costs of most of
these devices and disposables used are deemed high and in
many countries not reimbursed by the payer. The results
of our study demonstrate that this is true to a degree and
anaesthesia related costs are slightly, but significantly in-
creased. This may be relevant when comparing patients
without complications, but complication related costs
highly exceed those of monitoring and GDT has been
proven to reduce complications. This shows that even after
inclusion of these costs the GDT approach would be cost-
saving in populations with high postoperative morbidity.
Recently Bartha [11] published a large model based
analysis showing that goal directed hemodynamic ther-
apy would be a dominant strategy (i.e. both cost and life
saving) in octogenarians undergoing hip replacement.
Results from six meta-analyses and 17 research papers
(using different approaches and devices) were taken as
model inputs and an overall reduction of medical care
costs by 1882 € was demonstrated. In 2007 a health tech-
nology assessment of the oesophageal Doppler was pub-
lished by Mowatt [10]. As no formal economic data were
available the authors constructed a model based on eight
randomized single centre studies. The GDT approach wasfound likely to be cost-effective even for the worst model
scenario. Since then NICE has positively appraised this,
but also expanded it to include other devices (including
Vigileo/FloTrac). Our patient-specific “real world” data val-
idate these model based assumptions, even though the
exact monetary sums differ. Health care costs in Sweden
were taken as economic inputs in the former and ward/
ICU stay hospital costs in United Kingdom in the later
study. Our real, clinically derived economic data from the
Czech Republic seem to be closer to Mowatt’s worst sce-
nario but do not take into account purchasing power or
other translations of economic value.
When trying to interpret the results from our study it
is important to consider some specifics of the health
care system in the Czech Republic. For example, it’s
likely that the honoraria and costs of human work are
lower in former Eastern bloc European countries than
other Western systems. However, the costs of materials
and drugs used are potentially more similar to those in
the West. This is important to understand when consid-
ering those activities in where human work creates the
major part of care (e.g. clinical examinations, laboratory
or radiology assessments). However, the extent to which
any management practices are employed as standard of
care are also pivotal to interpreting economic data in
critical care. As a direct comparison of complications
costs are unavailable, we tried to calculate the additional
costs of different complications to enable this East-to-
West comparison. An Italian study concerning peri-
operative nutritional support in gastrointestinal surgery
(Braga et al. [14]) and a French analysis of nosocomial
infections costs [15] served as comparators. The first
study showed slightly shorter length of stay after colo-
rectal surgery compared to our GDT surgical group
(8.8 days in Braga vs. 9.9 days), but the average costs
were far higher in patients with complications (10,494 €
vs. 5,419 €) and to a lesser extent also in those without
complications (2,552 € in Braga compared to 1,956 € in
our study population). The costs of different individual
complications were 2–10 times higher than those ob-
served in our patients. The French study [15] allows a
better differentiation between major cost drivers point-
ing out the stated difference in costs of resources and
clinical examinations/procedures. Alas, costs of hospi-
talization (the major cost-driver in patients with infec-
tion in our population) are not indicated separately. The
reported additional charges were comparable in terms of
antimicrobial agent costs but conversely the clinical,
laboratory and radiology assessment expenditures were
2–10 times lower in our evaluation. According to these
results, higher cost-savings (resembling the data pub-
lished by Bartha [11] and Mowatt [10]) would have been
calculated in the same population when using Western
European countries complications related rates.
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lysis have to be commented in order to address potential
bias. We have excluded the costs of the preoperative
hospitalization from our analysis. The hemodynamic
intervention cannot affect the preoperative course and
hence we deemed these costs to be source of potential
bias in the assessment due to the relatively small sample
size and potential variability in cost. Similarly the costs
incurred by the primary surgery itself were excluded
from the analysis. Almost two thirds (79 patients, 66%)
of our patients underwent intra-abdominal vascular sur-
gery. The costs of the material used (grafts and sutures)
highly offset the other costs (i.e. anaesthesia, monitoring).
Their inclusion may have had a severe impact on the final
sum without being relevant to the subject under study. In
contrast, the costs of any further surgery related to poten-
tial complications were included in the analysis. Another
potential limitation is the additional medication given to
the patient. This is mostly charged as a lump sum per
hospitalization day. Only specific treatment groups (i.e.
antimicrobial agents, blood products, chemotherapeutics)
are directly reimbursed by the insurance companies.
When the treatment cost exceeds the per diem sum the
deficit is covered by the hospital budget. The knowledge
of the exact sum spent on the medication would be im-
portant for the hospital perspective but we were unable to
extract the data necessary for this calculation. This was
one of the major reasons for performing the healthcare
payer’s perspective analysis, which remains unaffected by
the missing information.
Retrospective evaluation of economic data poses another
potential flaw. We have managed to collect all the relevant
information in 116 (97%) patients. In four patients (three
from the Control group and one from the GDT group)
who were transferred into another healthcare facility, only
the data coming from the original hospital were available.
Social reasons played an important part in two of these
hospitalisations (one case in each group) and potentially ir-
relevant but in the remaining two cases (both from the
Control group) the patients spent 12 and 15 days in tertiary
hospitals to treat some resulting complications. We con-
sider this the conservative approach as it clearly biases
against GDT and although costs related to these hospitali-
zations were not available for assessment, the missing eco-
nomic data could only add to the observed benefit.
With regards to other limitations of our study, firstly,
the data are based on the costs directly charged to the
healthcare payer. Other costs to the hospital ward and staff,
patients and other possible subjects were not included as
well as the long term impact of potential decreased prod-
uctivity and other indirect costs. Second, the analysis was
based on the results of a single centre study performed in
the Czech Republic and although this undoubtedly leads to
better control of the study, transferability of results is notautomatically relevant to other centres. Finally, although
the point averages and trends for all results were consistent
in their direction (i.e. favouring GDT) only the difference
in the postoperative clinical examinations and procedures
reached statistical significance. In the original study design
the economic endpoints were not included in the statistical
power calculation and according to our observations a
study including more than 200 patients in each arm would
be necessary in order to reach a statistical significance in
major economic endpoints.
Nonetheless, in the absence of prospectively collected
economic data from other clinical studies we present here
what we consider to be some of the best evidence available
on which to assist clinical decision making where eco-
nomic constraints are present. We have actively attempted
to remove any potential bias and in order to produce a
conservative evaluation have selected the options that
favour the Control group when faced with a choice.
On balance, the implications for clinical practice based
on the results of this economic analysis alongside the
clinical data are strongly in favour of GDT. Where the
lack of proven economic benefit and need for initial in-
vestment are limitations for successful implementation
of perioperative GDT we have shown that a conservative
estimate produces a strong trend in favour of GDT.
Costs associated with GDT implementation were offset by
reduced costs of postoperative care and this may help to
convince hospital administrators and healthcare payers that
implementing perioperative GDT is not only beneficial for
patients’ health but also economically attractive.
Conclusion
Intraoperative fluid optimization with the use of stroke
volume variation and Vigileo/FloTrac system showed
not only a substantial improvement in morbidity, but
was associated with an economic benefit. The mean sav-
ings observed in the overall costs of postoperative care
(namely clinical care, costs of antimicrobial treatments
and ward stay costs) trend to offset the investment
needed to perform the GDT strategy and intraoperative
monitoring. In addition, important differences in com-
plication associated costs between East and West Euro-
pean countries were observed.
Key messages
 Perioperative goal directed therapy was associated not
only with clinical, but also important economic benefit.
 The cost-savings observed in the overall costs of
postoperative care (namely clinical care, costs of
antimicrobial treatments and ward stay costs) trend
to offset the investment needed to perform the
goal directed therapy strategy and intraoperative
monitoring.
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